Cargando…
Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease
BACKGROUND: The International Consortium for Health Outcomes Measurement has selected the self-administered comorbidity questionnaire (SCQ) to adjust case-mix when comparing outcomes of inflammatory bowel disease (IBD) treatment between healthcare providers. However, the SCQ has not been validated f...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591493/ https://www.ncbi.nlm.nih.gov/pubmed/37877105 http://dx.doi.org/10.1177/17562848231202159 |
_version_ | 1785124233302507520 |
---|---|
author | van Linschoten, Reinier Cornelis Anthonius Huberts, Anouk Sjoukje van Leeuwen, Nikki Hazelzet, Jan Antonius van der Woude, Janneke West, Rachel Louise van Noord, Desirée |
author_facet | van Linschoten, Reinier Cornelis Anthonius Huberts, Anouk Sjoukje van Leeuwen, Nikki Hazelzet, Jan Antonius van der Woude, Janneke West, Rachel Louise van Noord, Desirée |
author_sort | van Linschoten, Reinier Cornelis Anthonius |
collection | PubMed |
description | BACKGROUND: The International Consortium for Health Outcomes Measurement has selected the self-administered comorbidity questionnaire (SCQ) to adjust case-mix when comparing outcomes of inflammatory bowel disease (IBD) treatment between healthcare providers. However, the SCQ has not been validated for use in IBD patients. OBJECTIVES: We assessed the validity of the SCQ for measuring comorbidities in IBD patients. DESIGN: Cohort study. METHODS: We assessed the criterion validity of the SCQ for IBD patients by comparing patient-reported and clinician-reported comorbidities (as noted in the electronic health record) of the 13 diseases of the SCQ using Cohen’s kappa. Construct validity was assessed using the Spearman correlation coefficient between the SCQ and the Charlson Comorbidity Index (CCI), clinician-reported SCQ, quality of life, IBD-related healthcare and productivity costs, prevalence of disability, and IBD disease activity. We assessed responsiveness by correlating changes in the SCQ with changes in healthcare costs, productivity costs, quality of life, and disease activity after 15 months. RESULTS: We included 613 patients. At least fair agreement (κ > 0.20) was found for most comorbidities, but the agreement was slight (κ < 0.20) for stomach disease [κ = 0.19, 95% CI (−0.03; 0.41)], blood disease [κ = 0.02, 95% CI (−0.06; 0.11)], and back pain [κ = 0.18, 95% CI (0.11; 0.25)]. Correlations were found between the SCQ and the clinician-reported SCQ [ρ = 0.60, 95% CI (0.55; 0.66)], CCI [ρ = 0.39, 95% CI (0.31; 0.45)], the prevalence of disability [ρ = 0.23, 95% CI (0.15; 0.32)], and quality of life [ρ = −0.30, 95% CI (−0.37; −0.22)], but not between the SCQ and healthcare or productivity costs or disease activity (|ρ| ⩽ 0.2). A change in the SCQ after 15 months was not correlated with a change in any of the outcomes. CONCLUSION: The SCQ is a valid tool for measuring comorbidity in IBD patients, but face and content validity should be improved before being used to correct case-mix differences. |
format | Online Article Text |
id | pubmed-10591493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-105914932023-10-24 Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease van Linschoten, Reinier Cornelis Anthonius Huberts, Anouk Sjoukje van Leeuwen, Nikki Hazelzet, Jan Antonius van der Woude, Janneke West, Rachel Louise van Noord, Desirée Therap Adv Gastroenterol Original Research BACKGROUND: The International Consortium for Health Outcomes Measurement has selected the self-administered comorbidity questionnaire (SCQ) to adjust case-mix when comparing outcomes of inflammatory bowel disease (IBD) treatment between healthcare providers. However, the SCQ has not been validated for use in IBD patients. OBJECTIVES: We assessed the validity of the SCQ for measuring comorbidities in IBD patients. DESIGN: Cohort study. METHODS: We assessed the criterion validity of the SCQ for IBD patients by comparing patient-reported and clinician-reported comorbidities (as noted in the electronic health record) of the 13 diseases of the SCQ using Cohen’s kappa. Construct validity was assessed using the Spearman correlation coefficient between the SCQ and the Charlson Comorbidity Index (CCI), clinician-reported SCQ, quality of life, IBD-related healthcare and productivity costs, prevalence of disability, and IBD disease activity. We assessed responsiveness by correlating changes in the SCQ with changes in healthcare costs, productivity costs, quality of life, and disease activity after 15 months. RESULTS: We included 613 patients. At least fair agreement (κ > 0.20) was found for most comorbidities, but the agreement was slight (κ < 0.20) for stomach disease [κ = 0.19, 95% CI (−0.03; 0.41)], blood disease [κ = 0.02, 95% CI (−0.06; 0.11)], and back pain [κ = 0.18, 95% CI (0.11; 0.25)]. Correlations were found between the SCQ and the clinician-reported SCQ [ρ = 0.60, 95% CI (0.55; 0.66)], CCI [ρ = 0.39, 95% CI (0.31; 0.45)], the prevalence of disability [ρ = 0.23, 95% CI (0.15; 0.32)], and quality of life [ρ = −0.30, 95% CI (−0.37; −0.22)], but not between the SCQ and healthcare or productivity costs or disease activity (|ρ| ⩽ 0.2). A change in the SCQ after 15 months was not correlated with a change in any of the outcomes. CONCLUSION: The SCQ is a valid tool for measuring comorbidity in IBD patients, but face and content validity should be improved before being used to correct case-mix differences. SAGE Publications 2023-10-21 /pmc/articles/PMC10591493/ /pubmed/37877105 http://dx.doi.org/10.1177/17562848231202159 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research van Linschoten, Reinier Cornelis Anthonius Huberts, Anouk Sjoukje van Leeuwen, Nikki Hazelzet, Jan Antonius van der Woude, Janneke West, Rachel Louise van Noord, Desirée Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease |
title | Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease |
title_full | Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease |
title_fullStr | Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease |
title_full_unstemmed | Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease |
title_short | Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease |
title_sort | validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591493/ https://www.ncbi.nlm.nih.gov/pubmed/37877105 http://dx.doi.org/10.1177/17562848231202159 |
work_keys_str_mv | AT vanlinschotenreiniercornelisanthonius validityoftheselfadministeredcomorbidityquestionnaireinpatientswithinflammatoryboweldisease AT hubertsanouksjoukje validityoftheselfadministeredcomorbidityquestionnaireinpatientswithinflammatoryboweldisease AT vanleeuwennikki validityoftheselfadministeredcomorbidityquestionnaireinpatientswithinflammatoryboweldisease AT hazelzetjanantonius validityoftheselfadministeredcomorbidityquestionnaireinpatientswithinflammatoryboweldisease AT vanderwoudejanneke validityoftheselfadministeredcomorbidityquestionnaireinpatientswithinflammatoryboweldisease AT westrachellouise validityoftheselfadministeredcomorbidityquestionnaireinpatientswithinflammatoryboweldisease AT vannoorddesiree validityoftheselfadministeredcomorbidityquestionnaireinpatientswithinflammatoryboweldisease |